Terms: = Germ cell tumor AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Treatment
1402 results:
1. Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y cells.
Camoglio C; Balla J; Fadda P; Dedoni S
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611871
[TBL] [Abstract] [Full Text] [Related]
2. Cannabidiol induces erk activation and ROS production to promote autophagy and ferroptosis in glioblastoma cells.
Kim NY; Shivanne Gowda SG; Lee SG; Sethi G; Ahn KS
Chem Biol Interact; 2024 May; 394():110995. PubMed ID: 38583854
[TBL] [Abstract] [Full Text] [Related]
3. ACA-28, an erk MAPK Signaling Modulator, Exerts Anticancer Activity through ROS Induction in Melanoma and Pancreatic Cancer cells.
Takasaki T; Hamabe Y; Touchi K; Khandakar GI; Ueda T; Okada H; Sakai K; Nishio K; Tanabe G; Sugiura R
Oxid Med Cell Longev; 2024; 2024():7683793. PubMed ID: 38500550
[TBL] [Abstract] [Full Text] [Related]
4. EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma.
Yang E; Hong B; Wang Y; Wang Q; Zhao J; Cui X; Wu Y; Yang S; Su D; Liu X; Kang C
Cancer Lett; 2024 Apr; 588():216812. PubMed ID: 38490327
[TBL] [Abstract] [Full Text] [Related]
5. Zeaxanthin impairs angiogenesis and tumor growth of glioblastoma: An in vitro and in vivo study.
Lu F; Wu Q; Lei J; Zhou Y; Liu Y; Zhu N; Yu Y; Lin L; Hu M
Arch Biochem Biophys; 2024 Apr; 754():109957. PubMed ID: 38467357
[TBL] [Abstract] [Full Text] [Related]
6. A novel NIR fluorescent probe inhibits melanoma progression through apoptosis and erk/DRP1-mediated mitochondrial fission.
He Q; Li C; Ou Y; Pan Y; Yang X; Wang J; Liao H; Xiong X; Liu L; Sun C
Bioorg Chem; 2024 Apr; 145():107218. PubMed ID: 38377820
[TBL] [Abstract] [Full Text] [Related]
7. Investigating the therapeutic effects of novel compounds targeting inflammatory IL-1β and IL-6 signaling pathways in spinocerebellar ataxia type 3.
Chen IC; Chen WL; Chang KH; Lee JW; Lin TH; Lin W; Chen CM; Lee-Chen GJ
Eur J Pharmacol; 2024 Mar; 967():176370. PubMed ID: 38320719
[TBL] [Abstract] [Full Text] [Related]
8. The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.
Wu M; Hanly A; Gibson F; Fisher R; Rogers S; Park K; Zuger A; Kuang K; Kalin JH; Nocco S; Cole M; Xiao A; Agus F; Labadorf A; Beck S; Collard M; Cole PA; Alani RM
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38300709
[TBL] [Abstract] [Full Text] [Related]
9. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
[TBL] [Abstract] [Full Text] [Related]
10. KRAS is a molecular determinant of platinum responsiveness in glioblastoma.
Zuchegna C; Leone S; Romano A; Porcellini A; Messina S
BMC Cancer; 2024 Jan; 24(1):77. PubMed ID: 38225605
[TBL] [Abstract] [Full Text] [Related]
11. Dexamethasone Suppresses IL-33-exacerbated Malignant Phenotype of U87MG Glioblastoma cells
Ai J; Weng Y; Jiang L; Liu C; Liu H; Chen H
Anticancer Agents Med Chem; 2024; 24(5):389-397. PubMed ID: 38192141
[TBL] [Abstract] [Full Text] [Related]
12. Inhibition of TGF-β1-induced epithelial-mesenchymal transition in gliomas by DMC-HA.
Shi L; Wang Z; Rong J; Fei X; Li X; He B; Gong W; Qian J
Aging (Albany NY); 2023 Dec; 15(24):15183-15195. PubMed ID: 38154100
[TBL] [Abstract] [Full Text] [Related]
13. Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics.
Sokolov D; Sharda N; Banerjee A; Denisenko K; Basalious EB; Shukla H; Waddell J; Hamdy NM; Banerjee A
Curr Pharm Des; 2024; 30(1):31-47. PubMed ID: 38151840
[TBL] [Abstract] [Full Text] [Related]
14. Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma.
Guo T; Wu C; Zhang J; Yu J; Li G; Jiang H; Zhang X; Yu R; Liu X
Cell Commun Signal; 2023 Dec; 21(1):363. PubMed ID: 38115126
[TBL] [Abstract] [Full Text] [Related]
15. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar ME; Kim HJ; Kim DR
Signal Transduct Target Ther; 2023 Dec; 8(1):455. PubMed ID: 38105263
[TBL] [Abstract] [Full Text] [Related]
16. STING promotes invasion and migration of uveal melanoma through p38‑MAPK signaling.
Zhou X; Meng F; Xu B; Ma R; Cheng Y; Wu J; Qian J
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38099424
[TBL] [Abstract] [Full Text] [Related]
17. The Role of Bcl-2 and Beclin-1 Complex in "Switching" between Apoptosis and Autophagy in Human Glioma cells upon LY294002 and Sorafenib treatment.
Zając A; Maciejczyk A; Sumorek-Wiadro J; Filipek K; Deryło K; Langner E; Pawelec J; Wasiak M; Ścibiorski M; Rzeski W; Tchórzewski M; Reichert M; Jakubowicz-Gil J
Cells; 2023 Nov; 12(23):. PubMed ID: 38067099
[TBL] [Abstract] [Full Text] [Related]
18. erk hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.
Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
[TBL] [Abstract] [Full Text] [Related]
19. YTHDF3 Modulates EGFR/ATK/erk/p21 Signaling Axis to Promote Cancer Progression and Osimertinib Resistance of Glioblastoma cells.
Lee HH; Hsieh CC; Chang CC; Liao WT; Chi HC
Anticancer Res; 2023 Dec; 43(12):5485-5498. PubMed ID: 38030188
[TBL] [Abstract] [Full Text] [Related]
20. Drug dependence in cancer is exploitable by optimally constructed treatment holidays.
Maltas J; Killarney ST; Singleton KR; Strobl MAR; Washart R; Wood KC; Wood KB
Nat Ecol Evol; 2024 Jan; 8(1):147-162. PubMed ID: 38012363
[TBL] [Abstract] [Full Text] [Related]
[Next]
